Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

83%

5 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
5(83.3%)
Phase 1
1(16.7%)
6Total
Phase 3(5)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07017036Phase 3Not Yet Recruiting

Efficacy, Safety and Pharmacokinetic of Virchow IVIG in PID Patients

Role: lead

NCT02236793Phase 3Completed

A Phase 3 Clinical Trial to Assess the Effectiveness of BioChaperone PDGF-BB In the Treatment of Chronic Diabetic Foot Ulcer

Role: collaborator

NCT00500409Phase 3Completed

Safety and Efficacy of OSTEOFORM (rhPTH [1-34]) in Increasing Bone Mineral Density in Osteoporosis

Role: lead

NCT00496847Phase 3Completed

Efficacy and Safety of PERIOGEN in the Treatment of Periodontal Bone Defect

Role: lead

NCT01098357Phase 1Completed

Comparative Study of 3 Dose Regimens of BioChaperone to Becaplermin Gel for the Treatment of Diabetic Foot Ulcer

Role: lead

NCT00921375Phase 3Completed

Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia

Role: lead

All 6 trials loaded